Rapt Therapeutics brings to GSK ozureprubart, a long-acting antibody that inhibits the validated immunology target immunoglobulin E (IgE). If GSK is able to bring this drug to the market, it would complete with the blockbuster Genentech and Novartis allergy drug Xolair.
Getting the correct food allergy diagnosis leads to increased diet diversity and potentially improved nutrition when suspected allergies are ruled out, making it critical to take the right diagnostic approach from the beginning.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The FDA said promethazine hydrochloride, a generic drug used to manage allergies and motion sickness, should be administered by intramuscular injection. Intravenous injection can cause chemical irritation and tissue damage, an FDA alert states.
Seasonal allergy sufferers have a plethora of choices for treating the itching and redness affecting their eyes. An experimental Aldeyra Therapeutics drug that takes a new approach to blocking inflammation triggered by allergens has met the goals of a pivotal study and the biotech now plans to discuss the data with the FDA.
Tech entrepreneur Sean Parker just pledged $24 million to Stanford University to set up a new institute for allergy research, and it comes at an important time: We might not be too far, he says, from finding a treatment that’s curative. The new center will be called the Sean N. Parker Center for Allergy Research. It joins a […]